stockrowRedhill Biopharma Ltd. (RDHL) vs cbdMD, Inc. (YCBD)
- Redhill Biopharma Ltd. RDHL 0.43 0.00%
- cbdMD, Inc. YCBD 0.40 +2.56%
Redhill Biopharma Ltd. and cbdMD, Inc. are both Drug Manufacturers Specialty & Generic companies. cbdMD, Inc. is the larger, with a market value of $4.4M against $3.8M — 1.1× the size. cbdMD, Inc. grew revenue faster over the last twelve months: 10.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −14.7%) and the higher return on invested capital (0.00% vs −29.8%). Across the 16 metrics below, Redhill Biopharma Ltd. leads on 9 and cbdMD, Inc. on 7.
Valuation
| Metric | RDHL | YCBD | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | 0.00 | 0.19 | 2.08 |
| P/B | n/m | 0.49 | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | n/m | 12.22 |
| EV/Sales | 6.43 | 0.21 | 2.87 |
| Earnings yield | (142,015.51%) | (80.50%) | (15.94%) |
| Free cash flow yield | (231,394.02%) | (61.46%) | 0.00% |
Profitability
| Metric | RDHL | YCBD | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 35.16% | 57.68% | 53.51% |
| Operating margin | 0.00% | (13.87%) | 0.00% |
| Net margin | 25.20% | (14.71%) | (2.45%) |
| Free cash flow margin | 0.00% | (11.51%) | 0.00% |
| Return on equity | 0.00% | (43.01%) | (0.80%) |
| Return on assets | 0.00% | (26.73%) | (1.67%) |
| Return on invested capital | 0.00% | (29.78%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack